Niacin: The evidence, clinical use, and future directions

Current Atherosclerosis Reports

Volumn 14, Issue 1, 2012, Pages 49-59

  Villines, Todd C ^a,d   Kim, Andrew S ^a   Gore, Rosco S ^a   Taylor, Allen J ^b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Apolipoprotein B; Atherosclerosis; Atherosclerosis imaging; Combination lipid therapy; HDL cholesterol; Laropiprant; Lipids; Lipoprotein (a); Niacin; Nicotinic acid; Statin

Indexed keywords

CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSLIPIDEMIA; ENDOTHELIUM; ERYTHEMA; EVIDENCE BASED MEDICINE; FLUSHING; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; LIVER TOXICITY; PARESTHESIA; PATIENT EDUCATION; PRURITUS; SIDE EFFECT; URIC ACID BLOOD LEVEL; VASCULITIS;

ATHEROSCLEROSIS; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; NIACIN;

EID: 84857629402     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0212-1     Document Type: Article

References (77)

1. C Baigent A Keech PM Kearney, et al. 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 16214597 10.1016/S0140-6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM (Pubitemid 41416582)
2. CP Cannon BA Steinberg SA Murphy, et al. 2006 Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 438 445 16875966 10.1016/j.jacc.2006.04.070 1:CAS:528:DC%2BD28XntlWjsLo%3D (Pubitemid 44109954)
3. E Hulten JL Jackson K Douglas, et al. 2006 The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials Arch Intern Med 166 1814 1821 17000936 10.1001/archinte.166. 17.1814 1:CAS:528:DC%2BD28XhtFShu7jI (Pubitemid 44455162)
4. PM Ridker E Danielson FA Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 2207 18997196 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL
5. H Ghandehari S Kamal-Bahl ND Wong 2008 Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004 Am Heart J 156 112 119 18585505 10.1016/j.ahj.2008.03.005 1:CAS:528:DC%2BD1cXnvVGksro%3D
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
7. R Altschul A Hoffer JD Stephen 1955 Influence of nicotinic acid on serum cholesterol in man Arch Biochem 54 558 559 14350806 10.1016/0003-9861(55)90070-9 1:CAS:528:DyaG2MXktVCrtA%3D%3D
8. WP Castelli RJ Garrison PW Wilson, et al. 1986 Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA 256 2835 2838 3773200 10.1001/jama.1986.03380200073024 1:STN:280: DyaL2s%2FjslWktA%3D%3D (Pubitemid 17178361)
9. P Barter AM Gotto JC LaRosa, et al. 2007 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 1301 1310 17898099 10.1056/NEJMoa064278 1:CAS:528:DC%2BD2sXhtFSmtr3M (Pubitemid 47481452)
10. H Jafri AA Alsheikh-Ali RH Karas 2010 Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk Ann Intern Med 153 800 808 21173414
11. BJ Wu L Yan F Charlton, et al. 2010 Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids Arterioscler Thromb Vasc Biol 30 968 975 20167660 10.1161/ATVBAHA.109.201129 1:CAS:528:DC%2BC3cXkslKqsrk%3D
12. DH Blankenhorn SA Nessim RL Johnson, et al. 1987 Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 3233 3240 3295315 10.1001/jama.1987.03390230069027 1:STN:280:DyaL2s3is1GrtQ%3D%3D (Pubitemid 17078320)
13. E Bruckert J Labreuche P Amarenco 2010 Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 353 361 20079494 10.1016/j.atherosclerosis. 2009.12.023 1:CAS:528:DC%2BC3cXmslGnu78%3D This work is a recent meta-analysis that evaluates the impact of niacin, alone or in combination treatment, on all cardiovascular events and atherosclerosis progression from among 11 randomized controlled trials
14. L Cashin-Hemphill WJ Mack JM Pogoda, et al. 1990 Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up JAMA 264 3013 3017 2243429 10.1001/jama.1990.03450230049028 1:STN:280:DyaK3M%2Fls1Kmsg%3D%3D
15. JK Duggal M Singh N Attri, et al. 2010 Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease J Cardiovasc Pharmacol Ther 15 158 166 20208032 10.1177/1074248410361337 1:CAS:528: DC%2BC3cXnsVOqt7o%3D
16. HN Hodis WJ Mack L LaBree, et al. 1998 The role of carotid arterial intima-media thickness in predicting clinical coronary events Ann Intern Med 128 262 269 9471928 1:STN:280:DyaK1c7itFOrtw%3D%3D (Pubitemid 28090756)
17. AJ Taylor LE Sullenberger HJ Lee, et al. 2004 Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 3512 3517 15537681 10.1161/01.CIR.0000148955.19792.8D 1:CAS:528:DC%2BD2MXhtVGnt7s%3D (Pubitemid 39612564)
18. AJ Taylor HJ Lee LE Sullenberger 2006 The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2243 2250 17076985 10.1185/030079906X148508 1:CAS:528:DC%2BD28XhtlCku7jK (Pubitemid 44789989)
19. AJ Taylor TC Villines EJ Stanek, et al. 2009 Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2113 2122 19915217 10.1056/NEJMoa0907569 1:CAS:528:DC%2BD1MXhsFSnsLzP This work evaluates the comparative efficacy of niacin extended-release versus ezetimibe when added to chronic, stable statin therapy among high-risk patients for the endpoint of change in CIMT over 14 months
20. M Thoenes A Oguchi S Nagamia, et al. 2007 The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome Int J Clin Pract 61 1942 1948 17935553 10.1111/j.1742-1241.2007.01597.x 1:CAS:528: DC%2BD2sXhtl2gtLzN (Pubitemid 47573105)
21. TC Villines EJ Stanek PJ Devine, et al. 2010 The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration J Am Coll Cardiol 55 2721 2726 20399059 10.1016/j.jacc.2010.03.017 This work reports the final results of the ARBITER 6-HALTS trial and investigated the impact of niacin and ezetimibe cumulative drug exposure on change in CIMT
22. XQ Zhao RA Krasuski J Baer, et al. 2009 Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS) Am J Cardiol 104 1457 1464 19932775 10.1016/j.amjcard.2009.07.035 1:CAS:528:DC%2BD1MXhsVGlt7zO
23. MJ Chapman JS Redfern ME McGovern, et al. 2010 Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk Pharmacol Ther 126 314 345 20153365 10.1016/j.pharmthera.2010.01.008 1:CAS:528:DC%2BC3cXmsVeis7c%3D
24. A Gille ET Bodor K Ahmed, et al. 2008 Nicotinic acid: pharmacological effects and mechanisms of action Annu Rev Pharmacol Toxicol 48 79 106 17705685 10.1146/annurev.pharmtox.48.113006.094746 1:CAS:528:DC%2BD1cXisFynurY%3D (Pubitemid 351738150)
25. Wanders D, Judd RL. Future of GPR109A agonists in the treatment of dyslipidemia. Diabetes Obes Metabol. 2011.
26. T Rubic M Trottmann RL Lorenz 2004 Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin Biochem Pharmacol 67 411 419 15037193 10.1016/j.bcp.2003.09.014 1:CAS:528:DC%2BD2cXhtVaht7o%3D (Pubitemid 38236129)
27. M Lukasova C Malaval A Gille, et al. 2011 Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells J Clin Invest 121 1163 1173 21317532 10.1172/JCI41651 1:CAS:528:DC%2BC3MXjtVWku74%3D
28. SH Ganji S Qin L Zhang, et al. 2009 Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells Atherosclerosis 202 68 75 18550065 10.1016/j.atherosclerosis.2008.04.044 1:CAS:528:DC%2BD1cXhsFajsb3K This work reports potential pleiotropic mechanisms of niacin on the atherosclerosis process
29. AM Benjo RC Maranhao SR Coimbra, et al. 2006 Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment Atherosclerosis 187 116 122 16458316 10.1016/j.atherosclerosis.2005.08.025 1:CAS:528:DC%2BD28XltlentLw%3D (Pubitemid 43817002)
30. SJ Hamilton GT Chew TM Davis, et al. 2010 Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients Diab Vasc Dis Res 7 296 299 20667937 10.1177/1479164110376206
31. A Warnholtz P Wild MA Ostad, et al. 2009 Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study Atherosclerosis 204 216 221 18822413 10.1016/j.atherosclerosis.2008.08.003 1:CAS:528: DC%2BD1MXlsVKgtb0%3D
32. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-81.
33. PL Canner KG Berge NK Wenger, et al. 1986 Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1245 1255 3782631 10.1016/S0735-1097(86)80293-5 1:STN:280: DyaL2s%2FlvVCqtQ%3D%3D (Pubitemid 17208898)
34. G Brown JJ Albers LD Fisher, et al. 1990 Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1289 1298 2215615 10.1056/ NEJM199011083231901 1:STN:280:DyaK3M%2FhsFaksw%3D%3D (Pubitemid 20364735)
35. BG Brown XQ Zhao A Chait, et al. 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 1583 1592 11757504 10.1056/NEJMoa011090 1:CAS:528:DC%2BD3MXoslyhsLs%3D (Pubitemid 33126837)
36. EJ Whitney RA Krasuski BE Personius, et al. 2005 A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events Ann Intern Med 142 95 104 15657157
37. • The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J. 2011;161:538-43. This work describes the methods of the AIM-HIGH trial.
38. NHLBI Press Release on Stopping AIM-HIGH Trial. Available at http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792. Accessed June 5, 2011.
39. RH Knopp P Alagona M Davidson, et al. 1998 Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia Metabolism 47 1097 1104 9751239 10.1016/S0026-0495(98)90284-0 1:CAS:528:DyaK1cXmtVKlu7s%3D (Pubitemid 28428015)
40. H Bays A Shah Q Dong, et al. 2011 Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups Int J Clin Pract 65 436 445 21401833 10.1111/j.1742-1241.2010.02620.x 1:CAS:528:DC%2BC3MXktFeht7c%3D
41. D Maccubbin HE Bays AG Olsson, et al. 2008 Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia Int J Clin Pract 62 1959 1970 19166443 10.1111/j.1742-1241.2008.01938.x 1:CAS:528:DC%2BC3cXktFGntrc%3D
42. D Maccubbin MJ Koren M Davidson, et al. 2009 Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease Am J Cardiol 104 74 81 19576324 10.1016/j.amjcard.2009. 02.047 1:CAS:528:DC%2BD1MXotFCitL4%3D
43. J McKenney H Bays M Koren, et al. 2010 Safety of extended-release niacin/laropiprant in patients with dyslipidemia J Clin Lipidol 4 105 112 21122637 10.1016/j.jacl.2010.02.002
44. JF Paolini YB Mitchel R Reyes, et al. 2008 Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia Am J Cardiol 101 625 630 18308010 10.1016/j.amjcard.2007.10.023 1:CAS:528:DC%2BD1cXislams7Y%3D (Pubitemid 351625086)
45. J Danesh R Collins R Peto 2000 Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 1082 1085 10973834 1:STN:280:DC%2BD3cvls1Knuw%3D%3D
46. R Clarke JF Peden JC Hopewell, et al. 2009 Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 361 2518 2528 20032323 10.1056/NEJMoa0902604 1:CAS:528:DC%2BC3cXls1Gg This work reports two LPA genetic variants that were strongly and independently associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease, supporting a causal and genetic role for Lp(a) and coronary artery disease
47. JM McKenney LS McCormick EJ Schaefer, et al. 2001 Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia Am J Cardiol 88 270 274 11472706 10.1016/S0002-9149(01)01639-3 1:CAS:528:DC%2BD3MXltlOju70%3D (Pubitemid 32721954)
48. P Greenland JS Alpert GA Beller, et al. 2010 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 e50 e103 21144964 10.1016/j.jacc.2010.09.001
49. RS Birjmohun BA Hutten JJ Kastelein, et al. 2005 Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol 45 185 197 15653014 10.1016/j.jacc.2004.10.031 1:CAS:528:DC%2BD2MXkvFaisw%3D%3D (Pubitemid 40094724)
50. JR Guyton AC Goldberg RA Kreisberg, et al. 1998 Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia Am J Cardiol 82 737 743 9761083 10.1016/S0002-9149(98) 00448-2 1:CAS:528:DyaK1cXmsF2ls7k%3D (Pubitemid 28439633)
51. RH Karas ML Kashyap RH Knopp, et al. 2008 Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study Am J Cardiovasc Drugs 8 69 81 18422390 10.2165/00129784-200808020-00001 1:CAS:528:DC%2BD1cXns1artLs%3D (Pubitemid 351570857)
52. EA Brinton ML Kashyap AN Vo, et al. 2011 Niacin extended-release therapy in Phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis Am J Cardiovasc Drugs 11 179 187 21619381 10.2165/11592560-000000000- 00000 1:CAS:528:DC%2BC3MXpvFyntrg%3D
53. JM Keenan PL Fontaine JB Wenz, et al. 1991 Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia Arch Intern Med 151 1424 1432 2064495 10.1001/archinte. 1991.00400070172024 1:STN:280:DyaK3M3ptV2lug%3D%3D
54. JM Keenan CY Bae PL Fontaine, et al. 1992 Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin J Am Geriatr Soc 40 12 18 1727841 1:STN:280:DyaK38%2FptFKmsw%3D%3D
55. JM McKenney JD Proctor S Harris, et al. 1994 A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients JAMA 271 672 677 8309029 10.1001/jama.1994. 03510330050033 1:STN:280:DyaK2c7kt1Srtw%3D%3D
56. RB Norris 2006 "Flush-free niacin": dietary supplement may be "benefit-free" Prev Cardiol 9 64 65 16407706 10.1111/j.1520-037X.2006. 04736.x
57. GR Ziliotto G Lamberti A Wagner, et al. 1977 Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial Arch Sci Med Torino 134 359 394 345998 1:STN:280:DyaE1c7ktlOrsw%3D%3D (Pubitemid 8271133)
58. Z Benyo A Gille J Kero, et al. 2005 GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing J Clin Invest 115 3634 3640 16322797 10.1172/JCI23626 1:CAS:528:DC%2BD2MXhtlSqtLjK (Pubitemid 43121852)
59. Z Benyo A Gille CL Bennett, et al. 2006 Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells Mol Pharmacol 70 1844 1849 17008386 10.1124/mol.106.030833 1:CAS:528:DC%2BD28Xht1ylt73I (Pubitemid 44771899)
60. S Kamal-Bahl DJ Watson BM Ambegaonkar 2009 Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview Clin Ther 31 130 140 19243714 10.1016/j.clinthera.2009.01.011
61. A Goldberg P Alagona Jr DM Capuzzi, et al. 2000 Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia Am J Cardiol 85 1100 1105 10781759 10.1016/S0002-9149(00)00703-7 1:CAS:528:DC%2BD3cXislaqsbw%3D (Pubitemid 30214256)
62. AJ Taylor EJ Stanek 2008 Flushing and the HDL-C response to extended-release niacin J Clin Lipidol 2 285 288 21291745 10.1016/j.jacl.2008. 05.002
63. A Garg SM Grundy 1990 Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus JAMA 264 723 726 2374275 10.1001/jama.1990.03450060069031 1:STN:280:DyaK3czisFClsQ%3D%3D (Pubitemid 20246864)
64. AJ Taylor D Zhu LE Sullenberger, et al. 2007 Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2 Vasc Health Risk Manag 3 159 164 17583186 1:CAS:528:DC%2BD2sXntVSgtbk%3D (Pubitemid 46860725)
65. F Vittone A Chait JS Morse, et al. 2007 Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS) J Clin Lipidol 1 203 210 18591993 10.1016/j.jacl.2007.05.003 (Pubitemid 47055291)
66. A Linke M Sonnabend M Fasshauer, et al. 2009 Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance Atherosclerosis 205 207 213 19131065 10.1016/j.atherosclerosis.2008. 11.026 1:CAS:528:DC%2BD1MXnsFagtL8%3D This work reports the favorable impact of niacin extended-release on lipid parameters, adipocyte size, and insulin sensitivity in patients with impaired glucose tolerance
67. RB Goldberg TA Jacobson 2008 Effects of niacin on glucose control in patients with dyslipidemia Mayo Clin Proc 83 470 478 18380993 10.4065/83.4.470 1:CAS:528:DC%2BD1cXltFWhs78%3D (Pubitemid 351536472)
68. DR Gray T Morgan SD Chretien, et al. 1994 Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans Ann Intern Med 121 252 258 7741833 1:STN:280:DyaK2czhtFGgsA%3D%3D
69. AA Alsheikh-Ali RH Karas 2008 The safety of niacin in the US Food and Drug Administration adverse event reporting database Am J Cardiol 101 9B 13B 18375244 10.1016/j.amjcard.2008.02.027 1:CAS:528:DC%2BD1cXlslWgsbw%3D
70. CM Ballantyne MH Davidson J McKenney, et al. 2008 Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study) Am J Cardiol 101 1428 1436 18471454 10.1016/j.amjcard.2008.02.092 1:CAS:528:DC%2BD1cXlslyiurs%3D
71. XQ Zhao JS Morse AA Dowdy, et al. 2004 Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study) Am J Cardiol 93 307 312 14759379 10.1016/j.amjcard.2003.10.009 1:CAS:528:DC%2BD2cXptFantA%3D%3D (Pubitemid 38167426)
72. TA Jacobson 2010 A "hot" topic in dyslipidemia management-"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention Mayo Clin Proc 85 365 379 20360295 10.4065/mcp.2009.0535 1:CAS:528:DC%2BC3cXltlemsro%3D
73. H Oberwittler M Baccara-Dinet 2006 Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment Int J Clin Pract 60 707 715 16805757 10.1111/j.1368-5031.2006.00957.x 1:CAS:528:DC%2BD28XntF2ltrY%3D (Pubitemid 43811652)
74. AM Whelan SO Price SF Fowler, et al. 1992 The effect of aspirin on niacin-induced cutaneous reactions J Fam Pract 34 165 168 1737967 1:STN:280:DyaK387kvVenug%3D%3D
75. JK Wilkin O Wilkin R Kapp, et al. 1982 Aspirin blocks nicotinic acid-induced flushing Clin Pharmacol Ther 31 478 482 7060328 10.1038/clpt.1982.63 1:CAS:528:DyaL38XitFSlt7o%3D (Pubitemid 13097390)
76. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Available at http://clinicaltrials.gov/ct2/show/NCT00461630. Accessed June 5, 2011.
77. HC Shen SL Colletti 2009 Novel patent publications on high-affinity nicotinic acid receptor agonists Expert Opin Ther Pat 19 957 967 19552512 10.1517/13543770902991526 1:CAS:528:DC%2BD1MXns1eqtL0%3D